2 Epidemiology: Prevalence More than 30 million Americans suffer from varicose veins or a more serious form of venous disease called Chronic Venous Insufficiency (CVI). 1 Of the over 30 million Americans affected: Only 1.9 million seek treatment annually 1,2 While the vast majority remain undiagnosed and untreated CVI Prevalence *,1,2 30,000,000+ Seek Treatment *2 1,900,000 Treated 447,0002 (Table 30) *Statistics based on individuals over the age of Gloviczki P, et al. The care of patients with varicose veins and associated chronic diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. JVS; May Lee, A. US markets for varicose vein treatment devices Millennium Research Group, Inc. (A Decision Resource, Inc. Company), May 2011.
3 Prevalence and Etiology of Venous Insufficiency Venous reflux disease is 2x more prevalent than coronary heart disease (CHD) and 5x more prevalent than peripheral arterial disease (PAD) 1 Venous Reflux Disease Coronary Heart Disease Peripheral Arterial Disease Congestive Heart Failure Stroke Cardiac Arrhythmias Heart Valve Disease Brand FN, Dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins: the Framingham Study. Am J Prev Med 1988; 4(2):96-101
4 Possible Risk Factors and Symptoms of Venous Insufficiency Possible risk factors for venous insufficiency: Gender Age Heredity Pregnancy Standing occupation Obesity Prior injury or surgery Obstruction Symptoms of venous insufficiency: Leg pain, aching, or cramping Burning or itching of the skin Leg or ankle swelling Heavy feeling in legs Skin discoloration or texture changes Open wounds or sores Restless legs Varicose Veins
5 Etiology & Pathophysiology: CEAP C 0 : Asymptomatic. No visible or palpable signs of venous disease C 1 : Spider veins, reticular veins, telangiectasias C 6 : Open Skin Ulcers C 5 : Healed Skin Ulcers C 4 : Pigmentation, Lipodermatosclerosis C 3 : Edema C 2 : Varicose Veins Increased Pain and Reduced Quality of Life Photos courtesy of Rajabrata Sarkar, MD PhD
9 Venous return to right side of heart accomplished thru the actions of the calf muscle pump and venous valves.
12 Patient Assessment & Diagnosis Patient Assessment Ultrasound Diagnostic Study
17 Most commonly used for tributaries and reticular veins. Sodium tetradecyl sulfate, polidocanol, and hypertonic saline most commonly used agents Endothelial damage the result of either osmotic action or protein denaturation
19 Percentage of patients treated with the 1.0% polidocanol solution experienced the following mild to moderate adverse events: Closure Rate Reported pain Experienced retained coagulum (blood trapped in varicosities) 15.5% 27.6% 86.20% Experienced a DVT 8.6% Duration 8 Weeks CFVTE 6.9% Todd KL 3rd, et. al. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of incompetence. Phlebology; 2013 Jul 17
20 Duplex ultrasound response at 8 weeks: Placebo PEM 0.125% PEM 0.5% PEM 1.0% Duplex responders 1.8% 59.6% 83.3% % 2 The most commonly reported adverse events in %: Placebo PEM 0.125% PEM 0.5% PEM 1.0% Pain in extremity 10.5% 12.3% 5.0% 15.5% Retained coagulum % 11.7% 27.6% Thrombophlebitis superficial 1.8% 7.0% 13.3% 3.4% Deep vein thrombosis % CFVTE % 3.3% 6.9% Tenderness % 6.9% 1 P < P < compared to PEM 0.125% 3 CFVTE Common Femoral Vein Thrombus Extension. This is non-occlusive thrombi starting in the superficial vein and extending into the common femoral vein (similar to EHIT). Todd KL 3rd, et. al. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of incompetence. Phlebology; 2013 Jul 17
21 Belcaro, G, Nicolaides, AN, Ricci, A, et al. Endovascular sclerotherapy, surgery, and surgery plus sclerotherapy in superficial venous incompetence: a randomized, 10-year follow-up trial--final results. Angiology 2000; 51:529.
23 Tumescent needle Injection sites
24 The Venefit Procedure Using the ClosureFast Catheter Minimally invasive treatment option for patients with varicose veins and CVI Controlled and consistent radiofrequency (RF) energy to the ClosureFast catheter The catheter heats the vein wall and contracts the vein wall collagen, thereby occluding the vein
26 Proebstle Study 1,2 Multi-center 326 patients 99.6% occlusion at 6 months 90.0% occlusion at 5 years vs VANISH 2 Study 3 Multi-center 232 patients 87.9% occlusion at 8 weeks No data at 5 years 1 Dietzek A. RF Segmental ablation: 5-year data. Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (Veith Symposium) New York City; November 19, Proebstle et al. Three-year European follow-up of endovenous radiofrequency-powered segmental thermal ablation of the great saphenous vein with or without treatement of calf varicosities. Journal of Vascular Surgery; Todd KL 3rd, et. al. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of incompetence. Phlebology; 2013 Jul 17 *ClosureFast long-term data is shown for perspective only and not meant to imply that the data can be used in a head-to-head comparison with the data from the Vanish 2 study.
28 ClariVein TM *
29 Closure Rate 96.70% Duration 260 days Elias and Raines Mechanochemical Tumescentless Endovenous Ablation: Final Results of the Initial Clinical Trial. Phlebology 2012;27:67-72
30 Proebstle Study 1,2 Multi-center 396 limbs (326 patients) 99.6% occlusion at 6 months 90.0% occlusion at 5 years vs Elias Study 3 Single-center 30 limbs (29 patients) 96.7% occlusion at 260 days No data at 5 years 1 Dietzek A. RF Segmental ablation: 5-year data. Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (Veith Symposium) New York City; November 19, Proebstle et al. Three-year European follow-up of endovenous radiofrequency-powered segmental thermal ablation of the great saphenous vein with or without treatement of calf varicosities. Journal of Vascular Surgery; Elias and Raines Mechanochemical Tumescentless Endovenous Ablation: Final Results of the Initial Clinical Trial. Phlebology 2012;27:67-72 *ClosureFast long-term data is shown for perspective only and not meant to imply that the data can be used in a head-to-head comparison with the data from the Elias study.
31 Percent Occlusion 102.0% 100.0% 98.0% 96.0% 94.0% 92.0% 90.0% 88.0% 86.0% 84.0% 99.7% 87.9% 2-8 Weeks 98.6% 96.7% 3-6 Months 95.2% 94.2% 83.7% 90.0% 1 Year 5 Years Rasmussen et al. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. BJS 2011;98: Elias and Raines Mechanochemical Tumescentless Endovenous Ablation: Final Results of the Initial Clinical Trial. Phlebology 2012;27:67-72 Dietzek A. RF Segmental ablation: 5-year data. Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (Veith Symposium) New York City; November 19, 2013 Todd KL 3rd, et. al. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of incompetence. Phlebology; 2013 Jul 17 CLF EVLA MOCA UGFS
32 But is there an even better option to treat cvi?
34 FDA Cleared Cyanoacrylate Adhesives (not mutagenic, pyrogenic, hemolytic, sensitizing, irritating or cytotoxic) 2 Adhesive Date Use Cyanoacrylate (CA) Adhesives 1950s Wound adhesives Histoacryl Blue * 1980s Skin incisions Dermabond * 1998 Skin incisions/lacerations Ethicon OMNEX * 1998 Surgical adhesive Trufill * 2000 Liquid embolic system (AVM applications) Indermil * 2002 Skin incisions/lacerations 1 Pollak J, White R. The use of cyanoacrylate adhesives in peripheral embolization. J Vasc Interv Radiol 2001; 12: p Lawson J. et.al. Sapheon: the solution? Phlebology 2013;28Suppl1:2-9 Review article page 3 *Trademark of its respective owner.
35 Widely used medical tissue adhesive. 1 Antimicrobial effect against grampositive organisms. 2 Used safely on millions of patients with no reported carcinogenicity in humans (1986 study). 2 1 Lawson et al. Sapheon: the solution? Phlebology 2013, 28 Suppl 1:2-9, p3 2 Quinn J., Tissue Adhesives in Clinical Medicine, 2nd ed.(2005) p 34-35
36 Properties of Ideal Cyanoacrylate for Venous Closure Ideal viscosity Polymerize quickly Soft and elastic Maintains a strong bond Eliminate need for compression stockings* *Some patients may benefit from compression stockings post procedure.
37 When cyanoacrylate (CA) comes in contact with blood or plasma, it begins to polymerize. The body encapsulates the polymer as a foreign body. CA triggers inflammatory reaction in the vessel wall resulting in occlusion. Almeida J. et.al. Cyanoacrylate adhesive for the closure of truncal veins: 60 day swine model results. Vasc and Endovasc Surg (2011) 000(00) 1-5. DOI / p.1
38 Features of the VenaSeal Procedure Procedure Features Eliminates need for tumescent anesthesia. No risk of thermal injury. No post treatment compression stockings needed. 1,2 * Rapid return to normal activities. 2 1 Almeida, J et al., Two-year follow-up of first human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. Phlebology / Venous Forum of the Royal Society of Medicine Gibson, K. A Randomized, controlled study comparing cyanoacrylate adhesive embolization with radiofrequency ablation for treatment of incompetent great saphenous veins VeClose study. German Society of Phlebology, *Some patients may benefit from compression stockings post procedure.
39 Feasibility Study 1 escope 2 (European multicenter study) VeClose 3 (U.S. pivotal trial) 38 Patients, enrollment completed Aug , 3, 6, 12, 24 and 36 month follow-ups Primary endpoints: safety and efficacy 70 patients, enrollment completed Sept day, 1, 3, 6, 12, 24 and 36 month follow-ups Primary endpoint: closure w/o use of sedation, tumescent anesthesia or compression stockings 242 Patients, enrollment completed Sept day,1,3,6,12 months and 2,3 year follow-ups Primary endpoint: non-inferior to RFA in GSV closure Secondary endpoint: superiority in reduction of post procedural pain and bruising 1 Almeida, J et al., Two-year follow-up of first human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. Phlebology / Venous Forum of the Royal Society of Medicine Proebstle, T et al., The european multicenter cohort study on cyanoacrylate embolization of refluxing great saphenous veins. JVS: Venous and Lymphatic Disorders 2014; Accepted for publication. 3 Gibson, K. A Randomized, controlled study comparing cyanoacrylate adhesive embolization with radiofrequency ablation for treatment of incompetent great saphenous veins VeClose study. German Society of Phlebology, 2014.
40 Study Design Endpoints Closure Rates 1 Prospective, non-randomized single center study. To evaluate safety, efficacy and performance of the VenaSeal closure system for the treatment of incompetent saphenous veins. 38 patients enrolled. Safety: Rate of serious adverse events. Efficacy: Treatment success defined as complete occlusion of the treated vein segment using duplex ultrasound imaging. 1-Year: 92% 2-Year: 92% 3-Year: 92% 1 No adjunctive treatments for 6 months Almeida, J et al., Two-year follow-up of first human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. Phlebology / Venous Forum of the Royal Society of Medicine 2014.
41 Study Design Endpoints Prospective, non-randomized, multicenter study. To evaluate safety, efficacy of the VenaSeal closure system for the treatment of refluxing great saphenous veins. 70 patients enrolled. Follow-up assessments at 48 hours, 1, 3, 6, and 12 months. Duplex ultrasound closure without use of sedation, tumescent anesthesia or compression stockings. Closure Rates 1 6-Months: 94.3% 1-Year: 92.9% 1 No adjunctive treatments for 3 months Proebstle, T et al., The European Multicenter Cohort Study on Cyanoacrylate Embolization of Refluxing Great Saphenous Veins. JVS: Venous and Lymphatic Disorders 2014
42 Study Design Prospective, randomized 1:1 comparing the VenaSeal system (VSCS) to RFA (ClosureFast catheter). Purpose Demonstrate safety and effectiveness of the VenaSeal closure system (VSCS) for the treatment of lower extremity truncal reflux by showing non-inferiority at three months to RFA using the ClosureFast system. Closure Rates 1 3-Months: RFA: 94.3% VSCS: 98.9% 6-Months: RFA: 94.3% VSCS: 98.9% 1 No adjunctive treatments for 3 months Gibson, K. A Randomized, Controlled Study Comparing Cyanoacrylate Adhesive Embolization With Radiofrequency Ablation For Treatment Of Incompetent Great Saphenous Veins VeClose Study. German Society of Phlebology, 2014.
Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous vein Raghu Kolluri, MD, Director Vascular Medicine OhioHealth Riverside Methodist Hospital
Cox Health Venous Symposium June 2-3, 207 Mechanico-Chemical Ablation Non-thermal, Non-tumescent Venous Ablation Therapy ROBERT W. VORHIES, M.D., F.A.C.S. VASCULAR AND ENDOVASCULAR SURGERY ENDOVENOUS THERAPY
Understanding venous disease and treatment options for your patients Christopher Wulff, MD Understanding Chronic venous insufficiency (CVI) Important Statistics About CVI Affects all age groups 1 Is ten
Management of Superficial Reflux: Which option, when? Kathleen Gibson, MD Lake Washington Vascular Surgeons Bellevue, WA DISCLOSURES Kathleen Gibson, MD Consultant/Advisory Board: BTG, Medtronic Speakers
UNDERSTANDING VEIN DISEASE UC201706537 EN - For use in the U.S. only Do you need to sit down during your work day because your legs ache and/or swell? Do you miss out on doing the activities you love because
Disclosure of Conflict of Interest Chronic Venous Insufficiency Compression and Beyond Shawn Amyot, MD, CCFP Fellow of the Canadian Society of Phlebology Ottawa Vein Centre I do not have relevant financial
MOCA and GLUE: results and analyses of the RCTs Faculty disclosure Research Grant Medtronic Educational Grant mediusa Speakers Bureau Medtronic Pierre Fabre mediusa Medical Director Morrison Vein/Training
Additional Information S-55 Network providers are encouraged, but not required to participate in the on-line American Venous Forum Registry (AVR) - The First National Registry for the Treatment of Varicose
C SCOTT MCENROE Medical Director Vein Center of Virginia Sentara Medical Group April 27, 2018 Why Tumescent-Free Therapy Will Replace RF and Laser History of Venous Surgery 1950 s GSV/SSV stripping became
SAVE LIMBS SAVE LIVES! Endovenous Ablation for Chronic Wounds Frank J. Tursi, DPM, FACFS Clinical Associate Professor, University of Pennsylvania/Presbyterian Foot and Ankle Consultant, Philadelphia Flyers,
Venous Disease and Leg Ulcers Edward G Mackay MD St. Petersburg, FL NCVH 2015 Orlando, FL Disclosures Stocks Endoshape Sapheon Medical Advisory Board BTG, Boston Scientific Venous Leg Ulcer Most common
Conflict of Interest None American Venous Forum Guidelines on Superficial Venous Disease TOP 10 GUIDELINES 10. We recommend using the CEAP classification to describe chronic venous disorders. (GRADE 1B)
New Technologies in Superficial Vein Treatment Ariel D. Soffer, MD, FACC Associate Clinical Professor Florida International University Medical School Ariel Soffer, MD, FACC Bio Fellow of the American College
Clinical Review Criteria Treatment of Varicose Veins Radiofrequency Catheter Closure Sclerotherapy Surgical Stripping Trivex System for Outpatient Varicose Vein Surgery VenaSeal Closure System VNUS Closure
Current Management of Varicose Veins Michael J. Heidenreich, MD St. Joseph Mercy Hospital Ann Arbor, MI March 23, 2013 Nothing to disclose History Prevalence Anatomy Risk factors Clinical manifestations
FIND RELIEF FROM VARICOSE VEINS VenaSeal Sapheon Closure System UNDERSTAND Varicose veins may be a sign of something more severe. Your doctor can help you understand if you have this condition. may cause
FIND RELIEF FROM VARICOSE VEINS VenaSeal Closure System UNDERSTAND Varicose veins may be a sign of something more severe venous reflux disease Your doctor can help you understand if you have this condition.
Closurefast radiofrequency ablation for the treatment of GSV: Technique and outcome results Stephen Black Consultant Vascular Surgeon Clinical Lead for Venous and Lymphoedema Surgery Guy s and St Thomas
Thermal Techniques: Outcomes and Complications Meet The Experts: Thermal and Non-Thermal Ablation Techniques Joseph D. Raffetto MD VA Boston HCS, West Roxbury, MA, Harvard Medical School, Boston, MA; Brigham
Find Relief From Varicose Veins VenaSeal Closure System Understand Varicose veins may be a sign of something more severe venous reflux disease. Your doctor can help you understand if you have this condition.
RECOGNITION AND ENDOVASCULAR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY Paul Kramer, MD, FACC, FSCAI Liberty Cardiovascular Specialists Liberty Regional Heart and Vascular Center DISCLOSURES NONE Venous
OHTAC Recommendation Endovascular Laser Treatment for Varicose Veins Presented to the Ontario Health Technology Advisory Committee in November 2009 April 2010 Issue Background The Ontario Health Technology
Perforators: When to Treat and How Best to Do It? Eric Hager, MD September 10, 2015 Anatomy of Perforating veins Cadaveric studies 1 have shown >60 vein perforating veins from superficial to deep Normal
Endovenous Thermal vs. Endovenous Chemical Ablation What is the Best for the Patient T. Noppeney, J. Noppeney Center for Vascular Diseases: Outpatient Dept. Obere Turnstrasse, Dept. for Vascular Surgery
New Guideline in venous ulcer treatment: dressing, medication, intervention Kittipan Rerkasem, FRCS(T), PhD Department of Surgery Faculty of Medicine Chiang Mai University Topic Overview venous ulcer treatment
Subject: Document #: Publish Date: 12/27/2017 Status: Revised Last Review Date: 05/04/2017 Description/Scope This document addresses various modalities (listed below) for the treatment of valvular incompetence
Patient Information Venous Insufficiency and Varicose Veins What is a Varicose Vein? Gitter Vein Institute-revised 3/8/2016 2 Frequently Asked Questions What is the difference between varicose and spider
Varicose veins are a very common problem, generally appearing as twisting, bulging rope-like cords on the legs, anywhere from groin to ankle. Spider veins are smaller, flatter, red or purple veins closer
E S Insurance: 2 nd Insurance: Wait time: Date: A. Venous Health History Form Patient please complete questions 1-12 Patient Name: SSN#: Date of Birth: Primary Care Physician: What is the reason for your
Priorities Forum Statement Number 9 Subject Varicose Vein Surgery Date of decision September 2014 Date refreshed March 2017 Date of review September 2018 Relevant OPCS codes: L841-46, L848-49, L851-53,
VeClose trial Cyanoacylate closure vs. RF ablation 36-month results LINC 2018, Leipzig 31 st Jan 2018 Tobias Hirsch, Halle, Germany www.gefaessmedizin-hirsch.de Disclosure Tobias Hirsch I have the following
Non-Saphenous Vein Treatments Jessica Ochs PA-C Albert Vein Institute Colorado Springs and Lone Tree, CO I have no financial disclosures Types of Veins Treated Perforator Veins Tributary Veins Varicose
Are there differences in guidelines for management of CVD between Europe and the US? Bo Eklöf, MD, PhD Lund University Sweden Disclosures No disclosures Five sources for comparison SVS/AVF US guidelines
AMERICAN PODIATRIC MEDICAL ASSOCIATION THE NATIONAL ANNUAL SCIENTIFIC MEETING Friday, July 13 th 2018 Washington, D.C. CHRONIC VENOUS INSUFFICIENCY OF THE LOWER EXTREMITIES Clinical Pearls for the Podiatrist
Cyanoacrylate vs laser ablation. Turkish experience A. Kursat Bozkurt MD University of Istanbul Disclosure Speaker name: A. Kursat Bozkurt I have the following potential conflicts of interest to report:
Chattanooga s premiere VEIN CENTER Update on Venous Insufficiency, Varicose and Spider Veins 2016 Vincent W. Gardner, MD, FACS, RPVI Fellow, American College of Surgeons Board Certified, American Board
Clinical/Duplex Evaluation of Varicose Veins: Who to Treat? Sanjoy Kundu MD, FASA, FCIRSE, FSIR The Vein Institute of Toronto Scarborough Vascular Group Scarborough Vascular Ultrasound Scarborough Vascular
E S Insurance: 2 nd Insurance: Wait time: Date: A. Venous Health History Form Patient please complete questions 1-12 Patient Name: SSN#: Date of Birth: Primary Care Physician: What is the reason for your
Varicose Veins are a Symptom of Vein Disease. Now you can treat the source of your varicose veins with non-surgical endovenous laser treatment. Approximately 1 in 5 adult Americans suffer from superficial
Treatment of Varicose Veins Policy Number: Original Effective Date: MM.06.016 04/15/2005 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration 09/28/2018 Section: Surgery Place(s) of
Patient assessment and strategy making for endovenous treatment Raghu Kolluri, MD Director Vascular Medicine OhioHealth Riverside Methodist Hospital Columbus, OH Disclosures Current Medtronic Consultant/
Management of Venous Disease: an evidence based approach Disclosures Ed Boyle, MD Andrew Jones, MD Dr. Ed Boyle and Dr. Andrew Jones disclose Grants/research support: Medtronic, BTG International, Clearflow,
Service: Varicose Vein Treatments PUM 250-0032 Medical Affairs Policy Medical Policy Committee Approval 12/01/17 Effective Date 04/01/18 Prior Authorization Needed Yes Disclaimer: This policy is for informational
Varicose Vein Treatment Medicare C/D Medical Coverage Policy Origination Date: June 1, 1993 Review Date: February 15, 2017 Next Review: February, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Varicose veins
Which place for liquid sclerotherapy? Eberhard Rabe Department of Dermatology University of Bonn Germany Liquid Foam or GSV, foam / liquid sclerosant n diameter[mm] Follow up effectivity Hamel Desnos 2003
October 7, 2016 Craig Haug, MD JK MAC Medical Director NHIC, Corp. Hewlett Packard Enterprise 75 William Terry Dr., Hingham, MA 02043 Dear Dr. Haug: RE: Request for coverage and reimbursement for mechano-chemical
[Kreussler Studies] SUMMARY OF PIVOTAL STUDIES ON SCLEROTHERAPY OF VARICOSE VEINS FDA randomized controlled GCP blinded prospective multicenter [Sclerotherapy of Varices] Healthy legs with microfoam Chemische
MEDICAL POLICY SUBJECT: VARICOSITIES, TREATMENT PAGE: 1 OF: 10 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
MP9241 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes as indicated in 2.0, 3.0, 4.0 and 5.0 Additional Information: None Prevea360 Health Plan Medical Policy: Vein disease
Sclerotherapy in the Treatment of Venous Disease Zachary C. Schmittling, MD, FACS May 4, 2018 Sclerotherapy for Venous Disease: Overview 1 in 5 Americans Approximately 25% of women have some type of lower
How to choose which treatment method(s) to use for a particular varicose veins patient ESTABLISHING A TREATMENT PLAN Surgeon Dr G Mark Malouf Sydney Australia Following History and Physical examination
Arteries and veins Neil Wright Rob Fitridge Varicose veins Natural history, assessment and management Background Varicose veins are a common condition. Presentations can range from those that are noticed
Endothermal Ablation for Venous Insufficiency Dr. S. Kundu Medical Director The Vein Institute of Toronto Objective: remove the GSV from the circulation 1. Surgical - HL & stripping 2. Chemical sclerotherapy
Venous Insufficiency: The Changing Paradigm in Vascular Disease Robert Coronado, MD From Northern Heart & Vascular Institute Inc., Redding, California. ABSTRACT: Venous insufficiency is the most common
MEDICAL POLICY SUBJECT: VARICOSITIES, TREATMENT PAGE: 1 OF: 12 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
Page: 1 of 24 Last Review Status/Date: March 2015 Description A variety of treatment modalities are available to treat varicose veins/venous insufficiency, including surgical approaches, thermal ablation,
UNDERSTANDING VEIN PROBLEMS Varicose Veins, Chronic Venous Insufficiency, and DVT Do You Have a Vein Problem? Have you noticed pain or swelling in your legs? Do your symptoms worsen when you re sitting
02-33000-31 Original Effective Date: 02/15/02 Reviewed: 08/23/18 Revised: 09/15/18 Subject: Treatments for Varicose Veins/Venous Insufficiency THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins Nick Morrison, MD, a Kathleen Gibson, MD, b Michael Vasquez, MD, c Robert Weiss,
Varicose Veins Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Varicose Veins Professional Institutional Original Effective Date: January 1, 2004 Original
SAFETY AND FEASIBILITY OF MECHANO-CHEMICAL ABLATION OF VARICOSE VEINS: INITIAL RESULTS Michel M.P.J. Reijnen, M.D., Ph.D. Jean-Paul P.M. de Vries, M.D., Ph.D. Rijnstate Hospital, Arnhem, The Netherlands
Endo-Thermal Heat Induced Thrombosis (E-HIT) Michael Ombrellino MD FACS The Cardiovascular Care Group Clinical Associate Professor of Surgery Rutgers School of Medicine Objectives: What is E-HIT? How do
Cyanoacrylate Closure of Incompetent Great, Small and Accessory Saphenous Veins without the use of Post-Procedure Compression: a Post-Market Evaluation of the VenaSeal System (WAVES trial): Three Month
Neil Goldstein, MD Joseph Hewett, MD Board- Certified Physicians in Interventional, Diagnostic, and Vascular Radiology, Surgery, Vascular Surgery and Phlebology Varicose Vein Information Sheet PREVALENCE
Original Issue Date (Created): July 12, 2003 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
UnitedHealthcare Commercial Medical Policy SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS Policy Number: 2018T0447V Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
Corporate Medical Policy Varicose Veins of the Lower Extremities, Treatment for File Name: Origination: Last CAP Review: Next CAP Review: Last Review: varicose_veins_of_the_lower_extremities_treatment_for
Surgery or combined endolaser ablation and sclerotherapy for varicose veins, a new trend in a developing country (Iraq); a cohort study Bashar Hanna Azar (1) Ashur Yohanna Izac Oraha (2) Emad Abdulrahman
UnitedHealthcare Community Plan Medical Policy SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS Policy Number: CS117.N Effective Date: April 1, 2019 Instructions for Use Table
Treatment of Varicose Veins/Venous Insufficiency Corporate Medical Policy File name: Treatment of Varicose Veins/Venous Insufficiency File code: UM.SURG.03 Origination: 9/01/2010 Last Review: 03/2015 Next
Treatment of Venous ulcers utilizing n-butyl Cyanoacrylate (Super Glue) Awais Siddique MD Endovascular Radiologist AZH WAVE CENTERS Milwaukee WI Venous disease Etiology Are the result of Venous valvular
Disclosure of Conflict of Interest THE BASICS OF VENOUS INSUFFICIENCY: What You Should Know. An Introductory Lecture Donald Ives, MD, RVT, RPVI Board Certified Family Physician Diplomate of the American
UnitedHealthcare Commercial Medical Policy SURGICAL AND ABLATIVE PROCEDURES FOR VENOUS INSUFFICIENCY AND VARICOSE VEINS Policy Number: 2017T0447T Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS
Love your legs again Varicose Veins Veins are the vessels that return blood to the heart once it has circulated through the body (as opposed to arteries, which carry oxygen-rich blood from the heart to
MedStar Health, Inc. POLICY AND PROCEDURE MANUAL This policy applies to the following lines of business: MedStar Employee (Select) MedStar CareFirst PPO MedStar Health considers the treatment of Varicose
Clinical case Symptomatic anterior accessory great saphenous vein (AAGSV) reflux A 70 year-old female presents with symptomatic varicose veins on left leg for more than 10 years. She complains of heaviness,
Le varici recidive Recurrent varices: how to manage them? Marianne De Maeseneer MD PhD, Vascular Surgeon Department of Dermatology, Rotterdam, Netherlands & Faculty of Medicine and Health Sciences University
Patient Assessment :Venous History, Examination and Introduction to Doppler and PPG Dr Louis Loizou The 11 th Annual Scientific Meeting and Workshops of the Australasian College of Phlebology Tuesday 18
WHAT ABOUT FOAM SCLEROTHERAPY IN REVAS? Dr O CRETON Ste FOY LES LYON Disclosure of Interest I have the following potential conflicts of interest to report: Consulting: Medtronic WHAT ABOUT REVAS? Source
ABLATIVE AND SURGICAL TREATMENT FOR VENOUS INSUFFICIENCY POLICY Description of Service A variety of treatment modalities are available to treat varicose veins/venous insufficiency, including surgical approaches,
Varithena 3 rd February 2015 Forward-looking statement This presentation and information communicated verbally to you may contain certain projections and other forward-looking statements with respect to
Article The Management of Stasis Dermatitis and Chronic Venous Insufficiency in Patients Refractory to Conservative Therapies Kareem Halim, 1,2, * Mark J. McElroy, 1 and John A. Lewis 3 1 Havard Medical
The ClariVein OC Proprietary dual action device^ ClariVein OC is a specialty catheter for the infusion of physician-specified agents in the peripheral vasculature including for endovascular occlusion of